Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1971 Jul 10;105(1):42-46, 62.

Amantadine-HCl (Symmetrel) in the Management of Parkinson's Disease: A Double-Blind Cross-Over Study

André Barbeau, Harold Mars, Mihai I Botez, Marie Joubert
PMCID: PMC1931069  PMID: 4932544

Abstract

A double-blind cross-over study was carried out in 54 patients with Parkinson's disease to evaluate the efficacy of amantadine hydrochloride as compared to a lactose placebo in the management of this illness. Amantadine proved to be a useful and safe addition to the armamentarium when given in daily doses of 200 mg. Forty-eight per cent of patients experienced moderate to good results while 31% showed no measurable improvement. The quality of the improvement was inferior to that obtained with levodopa, but the side effects were fewer. The study could not demonstrate a useful synergistic action between the two drugs, nor could the response to amantadine be used to predict that with levodopa. On the other hand, the addition of amantadine was useful in a few instances where optimal therapeutic doses of levodopa could not be given because of side effects. The mechanism of action of amantadine is still conjectural, but there is strong evidence to indicate some interaction with central dopamine metabolism.

Full text

PDF
42

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARBEAU A., MURPHY G. F., SOURKES T. L. Excretion of dopamine in diseases of basal ganglia. Science. 1961 May 26;133(3465):1706–1707. doi: 10.1126/science.133.3465.1706-a. [DOI] [PubMed] [Google Scholar]
  2. BARBEAU A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J. 1962 Oct 13;87:802–807. [PMC free article] [PubMed] [Google Scholar]
  3. BERTRAND C., MARTINEZ N., HARDY J. LOCALISATION DES FONCTIONS LORS DE LA CHIRURGIE ST'ER'EOTAXIQUE PAR UNE VOIE D'ABORD FRONTALE PARASAGITTALE. Neurochirurgie. 1964 Sep-Oct;10:389–396. [PubMed] [Google Scholar]
  4. BIRKMAYER W., HORNYKIEWICZ O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787–788. [PubMed] [Google Scholar]
  5. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  6. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  7. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  8. Fieschi C., Nardini M., Casacchia M., Tedone M. E. Amantadine for Parkinson's disease. Lancet. 1970 May 2;1(7653):945–946. doi: 10.1016/s0140-6736(70)91065-2. [DOI] [PubMed] [Google Scholar]
  9. Fieschi C., Nardini M., Casacchia M., Tedone M. E., Reitano M., Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. doi: 10.1016/s0140-6736(70)92742-x. [DOI] [PubMed] [Google Scholar]
  10. Fletcher E. A., Redfern P. H. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J Pharm Pharmacol. 1970 Dec;22(12):957–959. doi: 10.1111/j.2042-7158.1970.tb08486.x. [DOI] [PubMed] [Google Scholar]
  11. Fünfgeld E. W. Amantadin-Wirkung bei Parkinsonismus: Klinik und Neurophysiologie. Dtsch Med Wochenschr. 1970 Sep 4;95(36):1834–1836. doi: 10.1055/s-0028-1108738. [DOI] [PubMed] [Google Scholar]
  12. Gilligan B. S., Veale J., Wodak J. Amantadine hydrochloride in the treatment of Parkinson's disease. Med J Aust. 1970 Oct 3;2(14):634–637. doi: 10.5694/j.1326-5377.1970.tb50241.x. [DOI] [PubMed] [Google Scholar]
  13. Godwin-Austen R. B., Frears C. C., Bergmann S., Parkes J. D., Knill-Jones R. P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Aug 22;2(7669):383–385. doi: 10.1016/s0140-6736(70)90002-4. [DOI] [PubMed] [Google Scholar]
  14. Grelak R. P., Clark R., Stump J. M., Vernier V. G. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science. 1970 Jul 10;169(3941):203–204. doi: 10.1126/science.169.3941.203. [DOI] [PubMed] [Google Scholar]
  15. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  16. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
  17. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Sep 12;2(7672):566–566. doi: 10.1016/s0140-6736(70)91365-6. [DOI] [PubMed] [Google Scholar]
  18. Joubert M., Barbeau A. Méthode de mesure de l'akinésie. Union Med Can. 1966 May;95(5):531–535. [PubMed] [Google Scholar]
  19. MCGEER P. L., BOULDING J. E., GIBSON W. C., FOULKES R. G. Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA. 1961 Sep 9;177:665–670. doi: 10.1001/jama.1961.03040360001001. [DOI] [PubMed] [Google Scholar]
  20. McDowell F., Lee J. E., Swift T., Sweet R. D., Ogsbury J. S., Kessler J. T. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Intern Med. 1970 Jan;72(1):29–35. doi: 10.7326/0003-4819-72-1-29. [DOI] [PubMed] [Google Scholar]
  21. Millac P., Hasan I., Espir M. L., Slyfield D. G. Amantadine in Parkinson's disease. Lancet. 1970 Feb 28;1(7644):464–464. doi: 10.1016/s0140-6736(70)90850-0. [DOI] [PubMed] [Google Scholar]
  22. Millac P., Hasan I., Espir M. L., Slyfield D. G. Treatment of Parkinsonism with L-dopa and amantadine. Lancet. 1970 Oct 3;2(7675):720–720. doi: 10.1016/s0140-6736(70)91987-2. [DOI] [PubMed] [Google Scholar]
  23. Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
  24. Parkes J. D., Zilkha K. J., Marsden P., Baxter R. C., Knill-Jones R. P. Amantadine dosage in treatment of Parkinson's disease. Lancet. 1970 May 30;1(7657):1130–1133. doi: 10.1016/s0140-6736(70)91211-0. [DOI] [PubMed] [Google Scholar]
  25. Pearce J., Rao N. S. Amantadine in Parkinsonism. Lancet. 1970 Nov 21;2(7682):1091–1092. doi: 10.1016/s0140-6736(70)90332-6. [DOI] [PubMed] [Google Scholar]
  26. Scatton B., Cheramy A., Besson M. J., Glowinski J. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol. 1970;13(1):131–133. doi: 10.1016/0014-2999(70)90194-9. [DOI] [PubMed] [Google Scholar]
  27. Schwab R. S., England A. C., Jr Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease. Trans Am Neurol Assoc. 1969;94:85–90. [PubMed] [Google Scholar]
  28. Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]
  29. Scotti G. Combined treatment of Parkinson's disease with amantadine and L-dopa. Lancet. 1970 Jun 27;1(7661):1394–1395. doi: 10.1016/s0140-6736(70)91298-5. [DOI] [PubMed] [Google Scholar]
  30. Shealy C. N., Weeth J. B., Mercier D. Livedo reticularis in patients with parkinsonism receiving amantadine. JAMA. 1970 Jun 1;212(9):1522–1523. [PubMed] [Google Scholar]
  31. Simon P., Malatray J., Boissier J. R. Antagonism by amantadine of prochlorpemazine-induced catalepsy. J Pharm Pharmacol. 1970 Jul;22(7):546–547. doi: 10.1111/j.2042-7158.1970.tb10567.x. [DOI] [PubMed] [Google Scholar]
  32. Stromberg U., Svensson T. H., Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. doi: 10.1111/j.2042-7158.1970.tb08487.x. [DOI] [PubMed] [Google Scholar]
  33. Vernier V. G., Harmon J. B., Stump J. M., Lynes T. E., Marvel J. P., Smith D. H. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol. 1969 Nov;15(3):642–665. doi: 10.1016/0041-008x(69)90066-0. [DOI] [PubMed] [Google Scholar]
  34. Völler G. W. Die Behandlung des Parkinson-Syndroms mit Amantadin. Dtsch Med Wochenschr. 1970 Apr 24;95(17):934–937. doi: 10.1055/s-0028-1108565. [DOI] [PubMed] [Google Scholar]
  35. Wendel H. A., Snyder M. T., Pell S. Trial of amantadine in epidemic influenza. Clin Pharmacol Ther. 1966 Jan-Feb;7(1):38–43. doi: 10.1002/cpt19667138. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES